论文部分内容阅读
目的:探讨小剂量秋水仙碱联合复方倍他米松治疗痛风性关节炎急性期的临床疗效。方法:选取舟山市定海区中心医院2017年6月至2019年3月收治的急性痛风性关节炎急性期患者100例为研究对象,采用随机数字表法分为常规组50例、联合给药组50例,常规组给予大剂量秋水仙碱治疗,联合给药组给予小剂量秋水仙碱联合复方倍他米松治疗,两组疗程均为7 d。比较两组临床疗效。结果:联合给药组总有效率为96.0%(48/50),高于对照组的76.0%(38/50),差异有统计学意义(χn 2=16.611,n P<0.01)。联合给药组肿胀关节数、压痛关节数、受影响关节总数、视觉模拟评分法评分分别为(0.80±0.06)个、(1.00±0.12)个、(1.36±0.21)个、(1.25±0.25)分,均显著优于常规组的(1.60±0.21)个、(1.60±0.35)个、(2.29±0.54)个、(3.02±0.58)分(n t=26.549、12.231、11.350、19.817,均n P<0.01)。联合给药组白细胞计数、红细胞沉降率、C反应蛋白分别为(7.51±1.03)×10n 9/L、(39.14±5.17)mm/h、(12.03±2.64)mg/L,均显著低于常规组的(8.63±1.54)×10n 9/L、(59.63±7.98)mm/h、(30.59±4.85)mg/L(n t=4.275、15.238、23.767,均n P<0.01)。联合用药组不良反应发生率为10.0%(5/50),低于常规组的26.0%(13/50),差异有统计学意义(χn 2=8.672,n P<0.01)。n 结论:小剂量秋水仙碱联合复方倍他米松治疗痛风性关节炎急性期的效果优于大剂量秋水仙碱,能有效缓解患者疼痛感,改善其各项检查指标,且不良反应发生率低。“,”Objective:To investigate the clinical efficacy of low-dose colchicine combined with compound betamethasone in the treatment of acute gouty arthritis.Methods:A total of 100 patients with acute gouty arthritis who received treatment in Dinghai Central Hospital from June 2017 to March 2019 were included in this study. They were randomly assigned to receive high-dose colchicine (conventional group, n n = 50) or low-dose colchicine combined with compound betamethasone (combined treatment group, n n = 50) for 7 days. Clinical efficacy was compared between the conventional and combined treatment groups.n Results:Total effective rate in the combined treatment group was significantly higher than that in the conventional group [96.0% (48/50) n vs. 76.0% (38/50), χn 2 = 16.611, n P < 0.01]. The number of swollen joints, the number of tender joints, the number of affected joints, Visual Analogue Scale score were 0.80 ± 0.06, 1.00 ± 0.12, 1.36 ± 0.21, 1.25 ± 0.25 respectively in the combined treatment group, which were significantly superior to those in the conventional group [1.60 ± 0.21, 1.60 ± 0.35, 2.29 ± 0.54, 3.02 ± 0.58, respectively, n t = 26.549, 12.231, 11.350, 19.817, all n P < 0.01). White blood cell count, erythrocyte sedimentation rate and C-reactive protein in the combined treatment group were (7.51 ± 1.03) × 10 n 9/L, (39.14 ± 5.17) mm/h, (12.03 ± 2.64) mg/L, which were significantly lower than those in the conventional group (8.63 ± 1.54) × 10n 9/L, (59.63 ± 7.98) mm/h, (30.59 ± 4.85) mg/L, n t = 4.275, 15.238, 23.767, all n P < 0.01). The incidence of adverse reactions in the combined treatment group was significantly lower than that in the conventional group [10.0% (5/50) n vs. 26.0% (13/50), χn 2 = 8.672, n P < 0.01).n Conclusion:Low-dose colchicine combined with compound betamethasone is superior to acute gouty arthritis in the treatment of acute gouty arthritis because it can more effectively alleviate patient's pain, better improves each examination index, and has lower incidence of adverse reactions.